Cannabis Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More – Compass Pathways (NASDAQ:CMPS), Clearmind Medicine (NASDAQ:CMND) Read more
Biotechnology Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline – Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI) Read more
Biotechnology FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement – Compass Pathways (NASDAQ:CMPS), Cybin (AMEX:CYBN) Read more
Biotechnology MindMed Receives FDA ‘Breakthrough Therapy’ Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials – Compass Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD) Read more
Biotechnology Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More – Compass Pathways (NASDAQ:CMPS), Blue Water Ventures Intl (OTC:BWVI) Read more
Biotechnology Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment – Compass Pathways (NASDAQ:CMPS) Read more
